Lexicon Pharmaceuticals: HC Wainwright raises Buy rating, PT to $4.

Lexicon Pharmaceuticals: HC Wainwright raises Buy rating, PT to $4.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has seen its stock price gain traction following an upgrade to a "Buy" rating by HC Wainwright & Co. The investment firm has also increased its target price for the biopharmaceutical company to $4, reflecting positive sentiment around the recent clinical data presented at the European Society of Cardiology (ESC) 2025 Congress in Madrid [1].

The post-hoc analysis of sotagliflozin, a dual sodium-glucose cotransporter 1 and 2 (SGLT-1 and SGLT-2) inhibitor, demonstrated consistent cardiovascular benefits across all age groups, including elderly patients. The study, pooling data from SCORED and SOLOIST-WHF trials with nearly 12,000 participants, showed a reduction in heart failure endpoints and major cardiovascular events regardless of age [1].

Sotagliflozin reduced the primary endpoint of total cardiovascular death and heart failure events with a hazard ratio of 0.72 overall, with similar efficacy in patients under 65 (HR: 0.68) and those 65 and older (HR: 0.73). For major adverse cardiovascular events (MACE), sotagliflozin demonstrated a hazard ratio of 0.80 across age groups [1].

The inclusion of patients over 75 years old is significant, as this population is frequently excluded from cardiovascular outcome trials despite having the highest event rates. This analysis helps fill an important evidence gap in geriatric cardiology and supports the drug's utility in a broader population than many competing therapies [1].

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. The company's unique genomics target discovery platform, Genome5000™, has identified more than 100 protein targets with significant therapeutic potential in a range of diseases [2].

The stock price of Lexicon Pharmaceuticals has shown resilience and growth, driven by the company's innovative pipeline and positive clinical outcomes. The upgrade by HC Wainwright & Co. reflects investor confidence in the company's ability to deliver on its promises and achieve long-term success in the biopharmaceutical sector [3].

References:
[1] https://www.stocktitan.net/news/LXRX/sotagliflozin-provides-consistent-relative-risk-reduction-in-heart-0940ndgo7eyy.html
[2] https://www.lexpharma.com
[3] https://www.hcwainwright.com